AsclepiX Therapeutics

Asclepi X Therapeutics

Biotechnology, 185 Hudson St, Baltimore, Maryland, 07311, United States, 1-10 Employees

asclepix.com

  • facebook
  • twitter
  • LinkedIn

Who is ASCLEPIX THERAPEUTICS

FRAUD ALERT: AsclepiX is aware of individuals representing job postings that are not legitimate positions. AsclepiX is NOT hiring at this time. AsclepiX Therapeutics is a clinical-stage b...

Read More

map
  • 185 Hudson St, Baltimore, Maryland, 07311, United States Headquarters: 185 Hudson St, Baltimore, Maryland, 07311, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2836

checked-icon Does something look wrong? Fix it. | View contact records from ASCLEPIX THERAPEUTICS

AsclepiX Therapeutics Org Chart and Mapping

Employees

Amir Shojaei

Chief Scientific Officer, Evp-Clinical Development

Scott Cerulli

Clinical Finance Manager

Sarah Pettorsson

Director, Business Operations and Administration

Steven Altschuler

Therapeutics Managing Director

Aleksander Popel

Founder and Chief Scientific Advisor

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AsclepiX Therapeutics

Answer: AsclepiX Therapeutics's headquarters are located at 185 Hudson St, Baltimore, Maryland, 07311, United States

Answer: AsclepiX Therapeutics's official website is https://asclepix.com

Answer: AsclepiX Therapeutics's revenue is $1 Million to $5 Million

Answer: AsclepiX Therapeutics's SIC: 2836

Answer: AsclepiX Therapeutics has 1-10 employees

Answer: AsclepiX Therapeutics is in Biotechnology

Answer: AsclepiX Therapeutics contact info: Phone number: Website: https://asclepix.com

Answer: FRAUD ALERT: AsclepiX is aware of individuals representing job postings that are not legitimate positions. AsclepiX is NOT hiring at this time. AsclepiX Therapeutics is a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases. Our lead candidate, AXT107, inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access